Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
A Phase 2 Open-Label, Multicenter, Rollover Study to evaluate the long term safety and tolerability of Pemigatinib and to provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy.
Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator.
Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures.
Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy.
Willingness to avoid pregnancy or fathering children.
You may not be if
Able to access pemigatinib commercially or outside of a clinical trial.
Permanently discontinued from the parent protocol for any reason.
Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.
Clareo Health | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
